ArticleStem cell research & therapy2026
The effect of cladribine-containing conditioning regimen on the efficacy and safety of allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparison of nutritional screening tools in pediatric patients undergoing hematopoietic stem cell transplantation.Frontiers in pediatrics · 2026Article
- CAR-T versus allogeneic transplantation as consolidation for B-cell acute lymphoblastic leukemia in remission: a propensity-score matched study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a curative option for children with refractory, relapsed, or high-risk acute lymphoblastic leukemia (ALL). Conditioning regimens are critical for ensuring engraftment and reducing post-transplantation relapse. Cladribine is a purine nucleoside analogue with antileukemic activity and central nervous system penetration. However, its role in conditioning regimens for pediatric ALL remains insufficiently defined.
methodsWe conducted a retrospective cohort study of 66 pediatric patients with ALL who underwent their first allo-HSCT at Sun Yat-sen Memorial Hospital between August 2018 and December 2023. Patients were stratified according to whether cladribine was incorporated into the conditioning regimen (CLAD + vs. CLAD-). Survival outcomes, relapse incidence, regimen-related toxicity, graft-versus-host disease (GVHD), and post-transplantation complications were compared. Sensitivity analyses were performed by restricting the control group to patients receiving non-total body irradiation, chemotherapy-based conditioning. Competing-risk methods were applied where appropriate.
resultsAmong the 66 children who underwent allo-HSCT, 38 patients received CLAD+ conditioning and 28 received CLAD- regimens. Conditioning intensity scores were significantly lower in the CLAD+ group (4.0 [3.0, 5.0] vs. 4.5 [4.0, 4.5], p < 0.001). Two-year overall survival or transplantation-related mortality did not differ significantly between the two groups. However, the 2-year relapse-free survival was significantly higher in the CLAD+ group (94.44% vs. 81.16%, p = 0.019), with a significantly lower 2-year cumulative incidence of relapse. These findings remained directionally consistent in sensitivity analyses that accounted for regimen heterogeneity and competing risks. Hematopoietic engraftment, the incidence of acute and chronic GVHD, and major post-transplantation complications were comparable between the two groups, while renal and gastrointestinal toxicities were significantly less frequent in the CLAD+ group.
conclusionIncorporation cladribine into conditioning regimens for pediatric ALL is associated with improved relapse-free survival and significantly lower frequencies of renal and gastrointestinal toxicities, without increasing the risk of transplant-related complications. Given the retrospective design and limited number of events, these promising findings warrant prospective validation in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.